Elan execs get $8M in stock awards

Elan's top executives got some good news recently: They've been awarded hundreds of thousands of stock options worth 6 million euros, or $8.16 million. The catch: They're spread out over the next three years, so to actually get their hands on all the stock, they have to stick around until 2013.

Elan had a big year in 2009: Its multiple sclerosis treatment Tysabri--sold in partnership with Biogen Idec--hit $1 billion in sales for the first time. And the company attracted a big partner in Johnson & Johnson, which took an 18 percent stake in the Irish drugmaker in return for an investment of more than $1 billion.

Along the way, CEO Kelly Martin saw his salary double to $1.67 million, plus a bonus of about $806,000. And now, he has 674,000 options priced at $7.05, which can be exercised over the next three years, plus another 124,000 in restricted stock units, which vest over the same period of time. Elan's stock was trading right around $7 at press time.

Other Elan execs got stock awards, too; they include CFO Shane Cooke, company secretary Liam Daniel and clinical portfolio chief Carlos Paya.

- see the story from the Irish Independent

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.